What does CJC-1295 do?

What CJC-1295 does at the receptor level

Growth hormone-releasing hormone is a peptide the hypothalamus releases to prompt the pituitary to secrete growth hormone. CJC-1295 is a synthetic analogue of that hormone, which places it in the GHRH-analogue class: it is built to engage the GHRH receptor rather than a different receptor family.

A 2026 critical review of peptide and peptide-analogue use in sport and bodybuilding lists CJC-1295 and sermorelin together as growth hormone-releasing hormone analogues, alongside growth hormone secretagogues such as ipamorelin and synthetic fragments such as Frag 176-191 and KPV. That classification is the clearest statement the supplied sources make about what CJC-1295 is: a GHRH-receptor analogue, grouped with the other releasing-hormone analogues rather than with the secretagogues.

The same review notes that the clinical evidence supporting peptide use in sport is limited, and that most published studies examine therapeutic applications under controlled regimens rather than the combined protocols common in bodybuilding. That limitation applies to this compound class as a whole and is worth holding onto before reading any mechanism claim as an outcome claim.

CJC-1295 vs sermorelin: two GHRH analogues

CJC-1295 vs sermorelin is a comparison within one class rather than across two. Both are synthetic analogues of growth hormone-releasing hormone, and the 2026 review groups them together under that heading. The practical difference the sources support is one of construct: CJC-1295 exists in a DAC-modified form carrying an albumin-binding group, while sermorelin is described in the analytical literature as one of the larger GHRH synthetic analogues studied for detection purposes.

A 2021 study on detecting GHRH synthetic analogues investigated the in vitro metabolism of four of the larger analogues, naming sermorelin, tesamorelin, CJC-1295 and CJC-1295 with drug affinity complex. Nineteen major in vitro metabolites were identified, synthesised and characterised, and used as reference materials to develop a liquid chromatography-tandem mass spectrometry method. Limits of detection were generally 1 ng/ml or less.

That study is an analytical-methods paper, not a comparative pharmacology trial, so it supports a statement about how the two analogues are distinguished in a laboratory rather than a statement about relative effect. The comparison table below keeps to what the sources establish.

What the evidence does not establish

The 2026 review states that peptides remain experimental substances with poorly defined long-term risks, and that most published studies examine therapeutic applications under controlled regimens rather than the combined protocols common in bodybuilding. It also notes that the largely unregulated supply chain compounds the problem, because products are often mislabeled or contaminated.

For this compound specifically, the research record lists three gaps: the frequent substitution of unmodified CJC-1295 for the DAC-modified analogue actually studied, the absence of long-term IGF-I and glucose-metabolism outcome data for either component, and documented content variability in unregulated preparations. A 2018 mass-spectrometric analysis of illicitly distributed growth-promoting preparations found discrepancies between declared and actual content, including incorrect peptide identity and variable amounts.

None of this is a claim that the compound does nothing. It is a statement about what the published record can and cannot support, which is the boundary this post stays inside.